Insulin × glycemic control

TrialCardiovascular diabetology2022

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 129 people · 2022

No range given

Reported lower glycemic control, no range given

−24.0

As reported

difference −24.0, no interval

One number in the abstract

the abstract, start to end

reduced insulin concentrations at week 24 (p < 0.001), and the

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−24.0
SGLT2 inhibitorsInsulinGlycemic control
1 / 3

1 paper cites it

2022
2023
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 35941584